Trial Profile
A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs CAR-T CEA therapy (Primary)
- Indications Liver metastases
- Focus Therapeutic Use
- Sponsors Sorrento Therapeutics
- 30 Mar 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Mar 2020 Planned initiation date changed from 1 Nov 2019 to 1 Nov 2021.
- 26 Jul 2019 Status changed from planning to not yet recruiting.